v503
Neoplasms, Anal
Merck Sharp & Dohme LLCvaccinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Neoplasms, Anal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Jessa Hospital | Phase 4 | BB |
Capecitabine Blokhin's Russian Cancer Research Center | Phase 3 | B |
MITOMYCINS Blokhin's Russian Cancer Research Center | Phase 3 | B |
Aijp (Arnebia Indigo Jade Pearl) University of California, San Francisco | Phase 2 | B |
Vgx-3100 Inovio Pharmaceuticals | Phase 2 | B |
View all 14 →
Same molecule, other indications
v503 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →